Roche’s oral GLP-1 receptor agonist CT-996 has weight loss of -6.1% within four weeksRoche has reported positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational,...
AI analysis finds huge public interest in GLP-1 drugs for weight loss and mental health benefitsUsing a large language models (LLMs) to analyse over 391,000 unique discussions related to glucagon-like peptide-1 (GLP-1) receptor...
Harnessing network of CNS proteins could increase effectiveness of GLP-1sA network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of...
Journal Watch 10/7/2024Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Most Americans do not use GLP-1s long enough to see meaningful weight-lossThe largest study to date has reported that despite the explosion in demand for GLP-1s, 58% of patients discontinue use before reaching a...
Pre-operative use of GLP-1s may reduce post-bariatric complicationsA combination of GLP-1 agonists taken before metabolic and bariatric surgery may help patients with extreme obesity lower the risk of...
Journal Watch 5/06/2024Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...